Halozyme Therapeutics, Inc.
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
7/10
|
17.7 | 57.21 | -69.06% | 16.5 | +7.3% |
| P/S |
|
6.01 | 33.44 | -82.02% |
|
|
| P/BV |
|
59.49 | 4.65 | 1179.93% |
|
|
| P/FCF |
|
15.3 | 42.56 | -64.06% |
|
|
| Ev/Ebitda |
|
15.07 | -17.68 | -185.26% |
|
|
| Ev/S |
|
7.68 | 22.52 | -65.91% |
|
|
| Ev/FCF |
|
17.06 | 47.58 | -64.16% |
|
|
| E/P |
|
0.0493 | 0.0188 | 162.2% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
10/10
|
50.94 | -13.3 | -483.02% | 53.88 | -5.45% |
| ROE |
|
336 | 9.69 | 3367.37% |
|
|
| ROA |
|
16.25 | 0.2896 | 5509.87% |
|
|
| ROIC |
|
42.26 | 7.63 | 453.55% |
|
|
| ROS |
|
33.96 | -25.08 | -235.43% |
|
|
| ROCE |
|
402.79 | 14.58 | 2663.57% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
3/10
|
3.63 | -3.62 | -200.1% | 3.7 | -2.12% |
| Nеt Debt/Ebitda |
|
3.27 | -4.05 | -180.69% |
|
|
| Debt/Ratio |
|
0.8836 | 0.1841 | 379.82% |
|
|
| Debt/Equity |
|
2.07 | 1.6 | 29.83% |
|
|
| Debt/Net Income |
|
5.44 | 0.9168 | 493.2% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 0.5448 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 0.7368 | -100% | ||
| DSI |
|
0 | 0.2387 | -100% |
|
|
| Average dividend growth |
|
0 | 1.55 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 0.4954 | -100% |
|
|
| Average percentage for payments |
|
15.92 | 43.64 | -63.52% |
|
|
| Difference from average difference in sector |
|
-0.5448 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
10/10
|
323.09 | 31.71 | 918.89% | ||
| Growth impulse Ebitda in 5 years |
|
-768.56 | -23.28 | 3201.37% | ||
| Growth impulse Net Income in 5 years |
|
-490.02 | -61.56 | 696% | ||
| Growth impulse FCF in 5 years |
|
-517.07 | -26 | 1888.73% | ||
| Growth impulse EPS in 5 years |
|
-519.25 | -63.63 | 716.05% |
IP Score
4.36/10
